Attendee search 

The project focuses on the research and development of anti-tumor photosensitizing drugs for photodynamic therapy, creating a research and development technology platform for photosensitizing drugs, and conducting clinical development and transformation of anti-tumor photosensitizing drugs. The new anti-tumor photosensitizer drugs developed by our team exhibited excellent tumor enrichment and high efficacy of photodynamic therapy. They have great potential for clinical development and application.

We are the flagship subsidiary of China Resources Group, engaging in the research and development, manufacturing, distribution and retail of a broad range of pharmaceutical and healthcare products.In 2018, our total revenue is HK$ 189.7 billion.
Currently CR Pharma Group is one of the TOP 3 pharmacetucial group in China, and our core competences is capabilities are marketing&sales(3000+ Sales Reps for RX and 3000+ Sales Reps for OTC and healthcare products, local Regulatory Affairs(Dedicated RA team), and great manufacturing facilities(40+ manufacturing sites in China, including API and finished products of all dosage forms, 4 sites are approved by US FDA and EMEA).
As a listed company in HK, CR Pharma has estalished consodiated business reputation in healtcare industry and capital market. And currently, nearly all top 50 MNC pharmacetical companies are our business partner in China, and business scope includes JV, Licensing, Commercial Distribution.

China Medical City (Taizhou Medical High-tech Zone) is located in Taizhou, an importent city in the Yangtze River Delta. China Medical city covers 30 km2 according its plan,consisting of functional zones of Scientific Research and Development, Manufacting,Exhibition and Trade, Helthcare, Education and Teaching, and Comprehensive Supporting. As the first national level life science hi-tech park, CMC has cooperated with over 70 famous life sicense research and development institutes and over 1300 companies.

隶属于浙江亚太药业股份有限公司,位于武汉光谷,从事新药研发、仿制药开发、临床研究服务等

Baiyu , founded in 2005, is a pharmaceutical enterprise engaged in developing, manufacturing and distributing of high-quality pharmaceutical products and APIs. With about 1000 employees, Baiyu now has 6 subsidiaries including Golden Ginkgo Pharmaceutical Co., Ltd., Ginkgolide Pharmaceuticals Co., Ltd., Sunshine Ginkgo Agriculture Co.Ltd., Sichuan Yu Jian Pharmaceutical Co., Ltd. and Ginkgo Yukang Informatics Co.,Ltd., Ginkgo Yuda Pharmaceutical Co.,Ltd., et al.

Currently,we have 8 finished pharmaceutical products and 2 APIs on the market. Based on Quality-by-Design concept, our manufacturing sites strictly comply with cGMP and EU GMP. Ginkgolide injection, Enoxaparin sodium injection, Lansoprazole for injection are our main products.

Baiyu is growing fastly and has been awarded“National High-tech Enterprise”,“Sichuan Famous Brand”and“Enterprises with the most investment value in Chinese pharmaceutical industry”in 3 consecutive years.

The culture of kindness, Taiji and phoenix leads the way we behave and our vision is to constantly benefiting mankind to enjoy life-long well-being.

na

江苏紫龙药业有限公司成立于2012年,由国家重点医药企业扬子江药业集团投资建设,是一家集
生产、质量、研发、推广于一体的现代化综合性制药企业。紫龙药业位于江苏省常州市新北区生命健
康产业园区内,紧靠沪宁高速、江宜高速、常州高铁站以及奔牛机场,地理位置得天独厚。总投资达
到16亿元,项目用地面积344亩,现有员工400余人。主要生产剂型包括：固体制剂、小容量注射剂、
冻干粉针剂等。截至目前,紫龙药业生产车间已全部通过新版GMP认证。

由扬子江药业集团2001年创建，为扬子江药业集团南京地区子公司，目前已发展为一家集科研、生产、营销于一体的国家高新技术企业，项目获批国家工程研究中心，江苏省院士工作站，建立了国际化研发体系，2015年成功入选南京市高端人才团队。

央企,从事药品研发,生产,销售,产品超过300个,2019年营业收入将近100亿元,共有400人的研发团队,全国分布19个生产基地,销售网络遍布全国各省,销售团队超过2500人。希望寻找高壁垒仿制药,高端技术平台,505b2,创新化药,生物药&生物类似物的合作机会,合作方式灵活。

Sino Biopharmaceutical Limited and its subsidiaries are the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain of pharmaceutical R&D platforms, intelligent production and strong sales systems. Its product offerings include a variety of biological drugs and chemical drugs, and it occupies an advantageous position in many potential therapeutic fields such as liver disease, tumors, cardiovascular and cerebrovascular diseases, orthopedics, digestive system, immune and respiratory diseases.

The company was listed on the Hong Kong Stock Exchange in 2000; selected as a component stock of the China Index of the MSCI Global Standard Index in 2013; selected as a component stock of the Hang Seng Index in 2018; selected as a component stock of the Hang Seng China Enterprises Index in 2019; and selected as a component stock of the Stock Connect Biotech 50 Index on the Hong Kong-Shanghai-Shenzhen Stock Connect and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. It was listed in the "Top 50 Global Pharmaceutical Companies" published by the authoritative American magazine "PharmExec" for two consecutive years in 2019 and 2020, and was also listed as one of the "Top 50 Best Companies in Asia Pacific" by Forbes (Asia) for four consecutive years from 2016 to 2019.

ChiaTai Tianqing Pharmaceutical Group Co., Ltd., the core company of Sino Pharmaceutical, ranked 6th in the 2019 China Chemical Pharmaceutical Industry Top 100 Comprehensive Strength List, Beijing Tide Pharmaceutical Co., Ltd. ranked 32nd; Nanjing ChiaTai Tianqing ranked 40th; ChiaTai Fenghai ranked 74th; and ChiaTai Pharmaceutical (Qingdao) ranked 87th. After many years of development, the group has become an important force leading the innovation and development of China's pharmaceutical technology and industry.

The company has been making outstanding achievements and has shown robust growth, which is inseparable from its great emphasis on R&D and innovation. The company currently leads the industry in R&D investment and product innovation capabilities. Based on policy trends, it focuses on the expansion of related areas centering around its main business, and has laid out a comprehensive general health development strategy. It has been continuously improving the efficiency of enterprise management, R&D, production and marketing by harnessing technologies and methods such as Big Data, artificial intelligence and fintech.

Sino Biopharmaceutical will inherit the values of "benefiting the country, the people, and the enterprise" held by Chiatai Group, undertake the mission of "health, happiness and longevity". Based on independent innovation, it will introduce global innovative technologies to consolidate its leading position in the Chinese market. It is hoped that insightful talents can share the development results of the pharmaceutical and healthcare industry. Let's join hands for a win-win future!